Tratamento Inovador Tópico Para a Leishmaniose Cutânea

Cutaneous leishmaniasis is present in 85 countries, affecting up to 1 million people worldwide each year and 350 million at risk for the disease. Being in use for about 70 years, drugs of choice in treating leishmaniases have been pentavalent antimonies, such as glucantime (Croft & Coombs 2003). Used for prolonged periods intravenously, they result in low efficacy rates associated with severe side effects, such as pancreatitis, cardiac arrhythmia, renal failure, hepatotoxicity and muscle pain. As a result, most patients tend to abandon treatment, which can lead to resistance to the disease. As a result, many patients tend to discontinue treatment.

Utilizing a soluble HSP90 inhibitor, 17-DMAG, either in its free form or encapsulated within nanoparticles, we have developed an innovative topical treatment for cutaneous leishmaniasis. This treatment can be applied as a standalone therapy or in conjunction with systemic treatment. The technology is designed to reduce the toxicity and adverse effects associated with current treatment approaches.

We seek partnerships with both national and international companies involved in the development, production, and marketing of GMP (Good Manufacturing Practices) drugs. Our goal is to collaborate on new innovations alongside Fiocruz. Additionally, we are open to licensing agreements with both domestic and global firms capable of manufacturing and commercializing our technology. We also welcome opportunities for financial partnerships to advance the technology through its developmental stages.